AZD-1390

N/A

Report date: 2025/11/21 17:16:18
NME

Base Information

Drug NameAZD-1390
Drug Alias NameRadiolabeled AZD-1390ATMBBBAZD-1390[11C]-AZD1390AZD1390
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATM inhibitorsRadiosensitizers
TargetsSerine-protein kinase ATM
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcUniversity Of Leeds
Inactive CompaniesThe Netherlands Cancer Institute
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsSarcoma

Other Information

ATC CodeN/A
Related LinksN/A